Antibodies against Anthrax: Mechanisms of Action and Clinical Applications
Open Access
Abstract
B. anthracis is a bioweapon of primary importance and its pathogenicity depends on its lethal and edema toxins, which belong to the A-B model of bacterial toxins, and on its capsule. These toxins are secreted early in the course of the anthrax disease and for this reason antibiotics must be administered early, in addition to other limitations. Antibodies (Abs) may however neutralize those toxins and target this capsule to improve anthrax treatment, and many Abs have been developed in that perspective. These Abs act at various steps of the cell intoxication and their mechanisms of action are detailed in the present review, presented in correlation with structural and functional data. The potential for clinical application is discussed for Abs targeting each step of entry, with four of these molecules already advancing to clinical trials. Paradoxically, certain Abs may also enhance the lethal toxin activity and this aspect will also be presented. The unique paradigm of Abs neutralizing anthrax toxins thus exemplifies how they may act to neutralize A-B toxins and, more generally, be active against infectious diseases.Keywords
This publication has 88 references indexed in Scilit:
- Pre- and postexposure protection against virulent anthrax infection in mice by humanized monoclonal antibodies to Bacillus anthracis capsuleProceedings of the National Academy of Sciences, 2010
- Structural basis for the unfolding of anthrax lethal factor by protective antigen oligomersNature Structural & Molecular Biology, 2010
- Anthrax toxin-neutralizing antibody reconfigures the protective antigen heptamer into a supercomplexProceedings of the National Academy of Sciences, 2010
- Neutralizing Monoclonal Antibodies Directed against Defined Linear Epitopes on Domain 4 of Anthrax Protective AntigenInfection and Immunity, 2009
- The Protective Antigen Component of Anthrax Toxin Forms Functional Octameric ComplexesJournal of Molecular Biology, 2009
- Potent neutralization of anthrax edema toxin by a humanized monoclonal antibody that competes with calmodulin for edema factor bindingProceedings of the National Academy of Sciences, 2009
- Selection and characterization of human antibodies neutralizing Bacillus anthracis toxinBioorganic & Medicinal Chemistry, 2008
- High-Affinity, Human Antibody-Like Antibody Fragment (Single-Chain Variable Fragment) Neutralizing the Lethal Factor (LF) of Bacillus anthracis by Inhibiting Protective Antigen-LF Complex FormationAntimicrobial Agents and Chemotherapy, 2007
- A Monoclonal Antibody to Bacillus anthracis Protective Antigen Defines a Neutralizing Epitope in Domain 1Infection and Immunity, 2006
- Selection of Bacillus anthracis isolates resistant to antibioticsJournal of Antimicrobial Chemotherapy, 2004